DNA microarray analysis of locally advanced rectal
adenocarcinomas: prediction of sensitivity to neoadjuvant
chemoradiotherapy

D 2007

DNA microarray analysis of locally advanced rectal adenocarcinomas: prediction of sensitivity to neoadjuvant chemoradiotherapy

GARAJOVÁ, Ingrid, Marek SVOBODA, Ondřej SLABÝ, Eva KREJČÍ, Ilona KOCÁKOVÁ et. al.

Základní údaje

Originální název

DNA microarray analysis of locally advanced rectal adenocarcinomas: prediction of sensitivity to neoadjuvant chemoradiotherapy

Název česky

DNA-čipová analýza lokálne pokročilých adenokarcinomů rekta:predikce senzitivity k neoadjuvatní chemoradioterapii

Autoři

GARAJOVÁ, Ingrid, Marek SVOBODA, Ondřej SLABÝ, Eva KREJČÍ, Ilona KOCÁKOVÁ, Markéta BEDNAŘÍKOVÁ, Roman ŠEFR a Rostislav VYZULA

Vydání

2007. vyd. Olomouc, III. dny diagnostické, prediktivní a experimentální onkologie. Sborník příspěvků. od s. 24-24, 1 s. 2007

Nakladatel

Solen

Další údaje

Jazyk

angličtina

Typ výsledku

Stať ve sborníku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Organizační jednotka

Lékařská fakulta

ISBN

978-80-244-1824-7

Klíčová slova anglicky

microarray;rectal adenocarcinoma;neoadjuvant therapy

Štítky

microarray, neoadjuvant therapy, rectal adenocarcinoma

Příznaky

Recenzováno

Změněno: 19. 12. 2007 01:38, prof. MUDr. Marek Svoboda, Ph.D.

Anotace

ORIG CZ

V originále

PURPOSE: Rectal cancer prognosis is favorable for surgically cured patients. To allow radical surgery removal of locally advanced rectal adenocarcinomas (LARA), neoadjuvant chemoradiotherapy is performed to reduce of tumor volume. This practice also increase a feasibility of sphincter sparing surgery. Unfortunately, not all patients, who underwent neoadjuvant chemoradiotherapy gain its benefits. Molecular characterization of sensitive or resistant patients should assist to oncologists in treatment decision by selecting those patients who will respond to neoadjuvant chemoradiotherapy, and who not. Patients who do not respond can be spared from toxicity, time, and expense associated with the treatment. The aim of our study was to identify differences in gene expression profiles of LARA treated with neoadjuvant chemoradiotherapy. METHODS: Eleven patients (pts) with LARA treated with neoadjuvant chemoradiotherapy based on fluoropyrimidines (fluorouracil or capecitabine) were included in our pilot study. Response to the therapy was determined on both level, 1. clinically (TNM) by transrectal ultrasonography and CT or MRI before and after therapy, and 2. histopathologically by TRG scoring system (tumor regression grade from 1 to 5) according to Mandard (Cancer 1994). Analyzed patients were divided into two groups: 1. Responders R (TRG 1 or 2 and clinical downstaging), and 2. Non-Responders NR (TRG 4 or 5, no-minimal downstaging). Tumor biopsies were obtained before initiation the therapy and stored in RNA later. RNA was extracted from each specimen and relative gene expression levels of 440 genes known to be involved in cancer biology were obtained by low density oligonucleotide microarrays. RESULTS: Gene expression data analysis based on SAM (Significance Analysis of Microarrays) and t test methods identified 7 genes (lipocalin 2, oncogene JUNB, cell cycle regulator RB1, p53 binding protein MDM4, calnexin, peroxisome proliferator activated receptor delta PPARD, mucin-like adhesion molecule CD24) with significantly up regulated expression in primary tumors of NR. In subsequent cluster analysis this group of genes was able to discriminate R and NR.CONCLUSION: Our preliminary data suggest that lowdensity oligonucleotide microarray technology should contribute to a better understanding of rectal cancer resistance at molecular level and facilitate prediction of tumor response to neoadjuvant chemoradiotherapy. IGA MZ CR NR/9076.

Česky

Publikace je pouze v anglickém jazyce.

Návaznosti

NR9076, projekt VaV

Název: Genomické profilování v predikci odpovědi na chemoradioterapii u pacientů s lokálně pokročilým karcinomem konečníku

Citovat

GARAJOVÁ, Ingrid, Marek SVOBODA, Ondřej SLABÝ, Eva KREJČÍ, Ilona KOCÁKOVÁ, Markéta BEDNAŘÍKOVÁ, Roman ŠEFR a Rostislav VYZULA. DNA microarray analysis of locally advanced rectal adenocarcinomas: prediction of sensitivity to neoadjuvant chemoradiotherapy. In III. dny diagnostické, prediktivní a experimentální onkologie. Sborník příspěvků. 2007. vyd. Olomouc: Solen, 2007, s. 24-24. ISBN 978-80-244-1824-7.

@inproceedings{746235,
   author = {Garajová, Ingrid and Svoboda, Marek and Slabý, Ondřej and Krejčí, Eva and Kocáková, Ilona and Bednaříková, Markéta and Šefr, Roman and Vyzula, Rostislav},
   address = {Olomouc},
   booktitle = {III. dny diagnostické, prediktivní a experimentální onkologie. Sborník příspěvků.},
   edition = {2007},
   keywords = {microarray;rectal adenocarcinoma;neoadjuvant therapy},
   language = {eng},
   location = {Olomouc},
   isbn = {978-80-244-1824-7},
   pages = {24-24},
   publisher = {Solen},
   title = {DNA microarray analysis of locally advanced rectal adenocarcinomas: prediction of sensitivity to neoadjuvant chemoradiotherapy},
   year = {2007}
}

TY  - JOUR
ID  - 746235
AU  - Garajová, Ingrid - Svoboda, Marek - Slabý, Ondřej - Krejčí, Eva - Kocáková, Ilona - Bednaříková, Markéta - Šefr, Roman - Vyzula, Rostislav
PY  - 2007
TI  - DNA microarray analysis of locally advanced rectal adenocarcinomas: prediction of sensitivity to neoadjuvant chemoradiotherapy
PB  - Solen
CY  - Olomouc
SN  - 9788024418247
KW  - microarray;rectal adenocarcinoma;neoadjuvant therapy
N2  - PURPOSE: Rectal cancer prognosis is favorable for surgically cured patients. To allow radical surgery removal of locally advanced rectal adenocarcinomas (LARA), neoadjuvant chemoradiotherapy is performed to reduce of tumor volume. This practice also increase a feasibility of sphincter sparing surgery. Unfortunately, not all patients, who underwent neoadjuvant chemoradiotherapy gain its benefits. Molecular characterization of sensitive or resistant patients should assist to oncologists in treatment decision by selecting those patients who will respond to neoadjuvant chemoradiotherapy, and who not. Patients who do not respond can be spared from toxicity, time, and expense associated with the treatment. The aim of our study was to identify differences in gene expression profiles of LARA treated with neoadjuvant chemoradiotherapy. METHODS: Eleven patients (pts) with LARA treated with neoadjuvant chemoradiotherapy based on fluoropyrimidines (fluorouracil or capecitabine) were included in our pilot study. Response to the therapy was determined on both level, 1. clinically (TNM) by transrectal ultrasonography and CT or MRI before and after therapy, and 2. histopathologically by TRG scoring system (tumor regression grade from 1 to 5) according to Mandard (Cancer 1994). Analyzed patients were divided into two groups: 1. Responders R (TRG 1 or 2 and clinical downstaging), and 2. Non-Responders NR (TRG 4 or 5, no-minimal downstaging). Tumor biopsies were obtained before initiation the therapy and stored in RNA later. RNA was extracted from each specimen and relative gene expression levels of 440 genes known to be involved in cancer biology were obtained by low density oligonucleotide microarrays. RESULTS: Gene expression data analysis based on SAM (Significance Analysis of Microarrays) and t test methods identified 7 genes (lipocalin 2, oncogene JUNB, cell cycle regulator RB1, p53 binding protein MDM4, calnexin, peroxisome proliferator activated receptor delta PPARD, mucin-like adhesion molecule CD24) with significantly up regulated expression in primary tumors of NR. In subsequent cluster analysis this group of genes was able to discriminate R and NR.CONCLUSION: Our preliminary data suggest that lowdensity oligonucleotide microarray technology should contribute to a better understanding of rectal cancer resistance at molecular level and facilitate prediction of tumor response to neoadjuvant chemoradiotherapy. IGA MZ CR NR/9076.
ER  -

GARAJOVÁ, Ingrid, Marek SVOBODA, Ondřej SLABÝ, Eva KREJČÍ, Ilona KOCÁKOVÁ, Markéta BEDNAŘÍKOVÁ, Roman ŠEFR a Rostislav VYZULA. DNA microarray analysis of locally advanced rectal adenocarcinomas: prediction of sensitivity to neoadjuvant chemoradiotherapy. In \textit{III. dny diagnostické, prediktivní a experimentální onkologie. Sborník příspěvků.}. 2007. vyd. Olomouc: Solen, 2007, s.~24-24. ISBN~978-80-244-1824-7.

Podrobný výpis o publikaci